摘要
目的探讨索拉非尼联合经导管动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)对原发性肝癌患者预后及细胞免疫功能的影响。方法选择2014年7月至2016年10月本院收治的原发性肝癌患者72例为研究对象,其中,32例采取TACE治疗(T组),40例采取索拉非尼联合TACE治疗(T+S组)。选择本院同期健康体检人群30例纳入对照组,检测上述三组研究对象治疗前后外周血T淋巴细胞亚群以及自然杀伤细胞(NK细胞)水平;参照改良后实体瘤疗效评价标准评价T组和T+S组的临床疗效。结果治疗前,T组和T+S组患者外周血CD3^+、CD4^+、NK细胞水平及CD4^+/CD8^+比值均显著低于对照组(P<0.05),CD8^+水平显著高于对照组(P<0.05),但T组和T+S组上述指标比较均无显著差异(P>0.05)。治疗4周后,T组和T+S组患者外周血CD3^+、CD4^+、NK细胞水平及CD4^+/CD8^+比值均显著升高(P<0.05),CD8^+水平显著降低(P<0.05),且T+S组患者外周血CD3^+、CD4^+、NK细胞水平及CD4^+/CD8^+比值均显著高于T组同期水平(P<0.05),CD8^+水平显著低于T组同期水平(P<0.05)。T+S组治疗有效率显著高于T组(P<0.05)。结论索拉非尼联合TACE治疗原发性肝癌可获得较好的近期疗效,并显著提高患者的细胞免疫功能。
Objective To investigate the effect of Sorafenib combined with transcatheter arterial chemoembolization(TACE)on prognosis and immune function in patients with primary liver cancer.Method72patients with primary liver cancer treated in our hospital from July2014to October2016were selected as the research objects,32patients treated with TACE(T group),40patients treated with Sorafenib combined with TACE(T+S group),30healthy people were selected as control group during the same period,analyzed the detection of peripheral blood T cell subsets and NK cell level among three groups,and evaluated the curative effects of T group and T+S group according to modified response evaluation criteria in solid tumors evaluation criterion.Result Before treatment,levels of the peripheral blood CD3+,CD4+,NK cell levels and CD4+/CD8+in T group and T+S group were significantly lower than those in control group(P<0.05),CD8+level in T group and T+S group were significantly higher than that in control group(P<0.05),there were no significant differences in CD3+,CD4+,CD8+,NK cell levels and CD4+/CD8+between T group and T+S group(P>0.05).After4weeks of treatment,the levels of CD3+,CD4+,NK cells and CD4+/CD8+in T group and T+S group improved significantly(P<0.05),CD8+in T group and T+S group decreased significantly(P<0.05),the levels of CD3+,CD4+,NK cell level and CD4+/CD8+in T+S group were significantly higher than those in T group(P<0.05),CD8+level in T+S group was significantly lower than that in T group(P<0.05).The effective rate of T+S group was significantly higher than T group(P<0.05).Conclusion Sorafenib combined with TACE has good clinical efficacy in patients with primary liver cancer,and can significantly improve the cellular immune function of patients.
作者
杨瑜婧
张慧娟
YANG Yu-jing;ZHNAG Hui-juan(Department of Hepatobiliary Surgery, the Affilated Hospital of Inner Mongolia Medical University, Hohhot 010050, China)
出处
《中国医学前沿杂志（电子版）》
2017年第6期121-125,共5页
Chinese Journal of the Frontiers of Medical Science(Electronic Version)
关键词
索拉非尼
经导管动脉化疗栓塞
原发性肝癌
细胞免疫功能
Sorafenib
Transcatheter arterial chemoembolization
Primary liver cancer
Cellular immunity function
